3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
64
Cisplatin
44
Cetuximab
26
Carboplatin
25
Paclitaxel
19
Magnetic Resonance Spectroscopy
19
Radiotherapy, Intensity-Modulated
17
Nivolumab
17
Radiotherapy
16
Specimen Handling
15
Docetaxel
14
Platinum
13
1,2-diaminocyclohexaneplatinum II citrate
12
Taxes
8
Fluorouracil
8
Biopsy
8
atezolizumab
6
Radiation
6
(225)Ac-DOTA-c(RGDyK)
6
dostarlimab
5
cemiplimab
5
Ipilimumab
5
Immunoglobulin G
5
Cyclophosphamide
5
Surgical Procedures, Operative
4
Standard of Care
4
Immune Checkpoint Inhibitors
4
Disulfides
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
ficlatuzumab
×
90 days
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled